SlideShare a Scribd company logo
1 of 27
Fever
National Pediatric Nighttime Curriculum
Written by Debbie Sakai, M.D.
Institution: Lucile Packard Children’s Hospital
Case 1
 4-month-old well-appearing girl admitted
for croup and respiratory distress.
Develops fever to 39.1.
What additional evaluation would you do at
this point?
Case 2
 12-year old boy with AML, in induction,
admitted for febrile neutropenia. He
had just received his first dose of
ceftazidime and vancomycin when he
developed another fever to 38.5, chills,
and new dizziness shortly after
receiving the antibiotics.
What would be the next steps in this
patient’s management?
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Which patients are high-risk for
sepsis?
 Neonates
 Transplant recipients
Bone marrow
Solid organ
 Oncology patients
Undergoing therapy, mucositis, central line
Most chemotherapy: nadir ~ 10 days after rx
 Asplenic patients, including sickle cell
Definition of fever
 38.0
 Neonates (< 12 months)
 Any immunocompromised patient
 Including transplant patients, patients with
immunodeficiencies, oncology patients (sustained ≥38 x 1
hour)
 38.5
 All other patients
 These are general guidelines, individual
patients/services may have different parameters
What etiologies cause fever?
 Infectious
 Inflammatory
 Oncologic
 Other: CNS dysfunction, drug fever
 Life-threatening conditions
Infectious
 Systemic
 Bacteremia, sepsis, meningitis, endocarditis
 Respiratory
 URI, sinusitis, otitis media, pharyngitis, pneumonia,
bronchiolitis
 Abdominal
 Urinary tract infection, abscess (liver, kidney, pelvis)
 Bone/joint infection
 Hardware infection
 Central line, VP shunt, G-tube
Inflammatory
 Kawasaki disease
 Juvenile inflammatory arthritis
 Lupus
 Inflammatory bowel disease
 Henoch-Schonlein purpura
Others
 CNS dysfunction
 Drug fever
Life-threatening conditions
 Sepsis, febrile neutropenia
 Vital sign instability, poor-perfusion, may have altered mental
status, disseminated intravascular coagulation
 Hemophagocytic lymphohistiocytosis
 Splenomegaly, bicytopenia, elevated ferritin, elevated
triglycerides, low fibrinogen, hemophagocytosis, low/absent NK
cell function, elevated soluble IL2 receptor
 Malignant hyperthermia
 Following administration of inhaled anesthetics or depolarizing
neuromuscular blockers (succinylcholine), at-risk patients
include those with myopathy
 Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Assessment
 Vital signs
 Repeat physical exam
 Overall appearance (sick, toxic)
 Central/peripheral lines
 Incisions/wounds
 VP shunt/tracheostomy/gastrostomy tube
 Oral mucosa/perineal area for neutropenic patients
 Perfusion
 Call for help if concerning vital signs/exam
 Fellow or attending
 Rapid response team (RRT)/PICU
Laboratory evaluation
 What would you do if the patient has
hardware (VP shunt, tracheostomy,
gastrostomy tube) or central line?
CBC with differential
Blood culture
CSF (tap VP shunt)
Laboratory evaluation
 What would you do if the patient has a
high risk for sepsis?
Immunocompromised
Transplant recipient
Oncology patient
CBC with differential
Blood culture
Urinalysis and urine culture
Laboratory evaluation
 What would you do for an infant ≤ 2
months of age?
CBC with differential
Blood culture
Catheterized urinalysis and urine culture
Lumbar puncture
Laboratory evaluation
 Who needs a urinalysis and urine culture?
Circumcised males < 6 months
Uncircumcised males < 1 year
Females < 2 years
Immunocompromised patients
Patients with history of UTI/pyelonephritis
Laboratory evaluation
 Who needs a lumbar puncture?
 Neonates ≤ 2 months
 Ill-appearing
 Altered mental status
 What tests do you send?
 Gram stain and culture
 Cell count and differential
 Protein and glucose
 Extra tube for additional studies
 Enteroviral PCR, HSV PCR, CA encephalitis project
Laboratory evaluation
 Consider CRP, ESR
 Consider PT/PTT, fibrinogen
 Consider chest x-ray
 Consider nasopharyngeal DFA
 For immunosuppressed patients consider:
Viral PCR studies (ie CMV, EBV, HHV6)
Additional imaging (ie ultrasound, CT scan)
Objectives
 To determine which patients are at high
risk of developing sepsis.
 To assess patient with fever.
 To initiate empiric therapy.
Treatment for non-high risk patients
 May not need empiric antibiotics
 Consider the following issues:
Is patient clinically stable?
Are the screening laboratory studies
suggestive of infection?
Treatment for patients with central
lines
 Ceftriaxone
 Vancomycin
Treatment for neonates ≤ 2 months
 If < 28 days old
Ampicillin AND cefotaxime OR
Ampicillin AND gentamicin
 Consider acyclovir
 If 29-60 days old
Ceftriaxone ± Ampicillin OR Vancomycin
Until CSF results are known (cell count,
protein, glucose), initiate therapy with
meningitic dosing regimen
Treatment for febrile neutropenia
 Broad-spectrum antibiotics with Pseudomonas
coverage
 Ex: use ceftazidime or piperacillin-tazobactam
 Consider double coverage for possible resistant
Pseudomonas
 Ex: add amikacin or tobramycin
 Consider gram-positive coverage (central line,
skin infections)
 Ex: add vancomycin
 Consider anaerobic coverage (mucositis,
typhlitis)
 Ex: use piperacillin-tazobactam or add clindamycin
Take home points
 Infections are the most common cause of fever
in children
 During assessment of a child with fever, pay
close attention to vital sign changes, overall
appearance, and potential sites of infection
 Closely monitor for clinical decompensation after
antibiotic administration, particularly in patients
at high-risk of developing sepsis
References
 Baraff LJ. Management of fever without source in infants and
children. Ann Emerg Med. 2000. 36:602-14.
 Meckler G, Lindemulder S. Fever and neutropenia in pediatric
patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.
 Palazzi EL. Approach to the child with fever of unknown origin.
UpToDate. 2011
 Palazzi DL. Etiologies of fever of unknown origin. UpToDate.
2011.
 Tolan R. Fever of unknown origin: A diagnostic approach to this
vexing problem. Clin Pediatr. 2010;49:207-13.

More Related Content

Similar to fever-presentation.ppt

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinaraKinara Kenyoru
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsistbf413
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsAli Musavi
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TBAbhijeet Deshmukh
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022vetindex4
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...intensivecaresociety
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaNilesh Kucha
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Gamal Agmy
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaHarsha Vardhan
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAIJoseph Helms
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia NITISH SHAH
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children Pediatrics
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptxShamiPokhrel2
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptxShamiPokhrel2
 

Similar to fever-presentation.ppt (20)

Neonatal sepsis kinara
Neonatal sepsis kinaraNeonatal sepsis kinara
Neonatal sepsis kinara
 
Fever infants
Fever infantsFever infants
Fever infants
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
 
Febrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patientsFebrile neutropenia - Infections in cancer patients
Febrile neutropenia - Infections in cancer patients
 
National guidelines on pediatric TB
National guidelines on pediatric TBNational guidelines on pediatric TB
National guidelines on pediatric TB
 
Mod 6 case 2022
Mod 6 case 2022Mod 6 case 2022
Mod 6 case 2022
 
Febrile neutropaenia
Febrile neutropaeniaFebrile neutropaenia
Febrile neutropaenia
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
UK Joint Specialist Guidelines on the Diagnosis and Management of Acute Menin...
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Case Presentation MAI
Case Presentation MAICase Presentation MAI
Case Presentation MAI
 
Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia Pediatric community Acquired Pneumonia
Pediatric community Acquired Pneumonia
 
Lymphadenopathy in children
Lymphadenopathy in children Lymphadenopathy in children
Lymphadenopathy in children
 
HAP
HAPHAP
HAP
 
Sepsis
SepsisSepsis
Sepsis
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 
20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx20-COVID_19_and_MIS-C(1).pptx
20-COVID_19_and_MIS-C(1).pptx
 
Emergencies in oncology
Emergencies in oncologyEmergencies in oncology
Emergencies in oncology
 

More from Kiramat2

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptxKiramat2
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptKiramat2
 
fever-presentation (1).ppt
fever-presentation (1).pptfever-presentation (1).ppt
fever-presentation (1).pptKiramat2
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.pptKiramat2
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfKiramat2
 

More from Kiramat2 (6)

02 Epilepsy in children.pptx
02 Epilepsy in children.pptx02 Epilepsy in children.pptx
02 Epilepsy in children.pptx
 
THYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.pptTHYROID DISEASES FOR STUDENTS king saud.ppt
THYROID DISEASES FOR STUDENTS king saud.ppt
 
fever-presentation (1).ppt
fever-presentation (1).pptfever-presentation (1).ppt
fever-presentation (1).ppt
 
08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt08_pediatric_leukemias.ppt
08_pediatric_leukemias.ppt
 
neonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdfneonatal hypoglycemia transient.pdf
neonatal hypoglycemia transient.pdf
 
CMPA.pdf
CMPA.pdfCMPA.pdf
CMPA.pdf
 

Recently uploaded

Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designMIPLM
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementmkooblal
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxLigayaBacuel1
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Celine George
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxDr.Ibrahim Hassaan
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Quarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayQuarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayMakMakNepo
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.arsicmarija21
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...JhezDiaz1
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxAnupkumar Sharma
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfphamnguyenenglishnb
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 

Recently uploaded (20)

Keynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-designKeynote by Prof. Wurzer at Nordex about IP-design
Keynote by Prof. Wurzer at Nordex about IP-design
 
Hierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of managementHierarchy of management that covers different levels of management
Hierarchy of management that covers different levels of management
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
Planning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptxPlanning a health career 4th Quarter.pptx
Planning a health career 4th Quarter.pptx
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptx
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
Quarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up FridayQuarter 4 Peace-education.pptx Catch Up Friday
Quarter 4 Peace-education.pptx Catch Up Friday
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptxMULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
MULTIDISCIPLINRY NATURE OF THE ENVIRONMENTAL STUDIES.pptx
 
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfAMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 

fever-presentation.ppt

  • 1. Fever National Pediatric Nighttime Curriculum Written by Debbie Sakai, M.D. Institution: Lucile Packard Children’s Hospital
  • 2. Case 1  4-month-old well-appearing girl admitted for croup and respiratory distress. Develops fever to 39.1. What additional evaluation would you do at this point?
  • 3. Case 2  12-year old boy with AML, in induction, admitted for febrile neutropenia. He had just received his first dose of ceftazidime and vancomycin when he developed another fever to 38.5, chills, and new dizziness shortly after receiving the antibiotics. What would be the next steps in this patient’s management?
  • 4. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 5. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 6. Which patients are high-risk for sepsis?  Neonates  Transplant recipients Bone marrow Solid organ  Oncology patients Undergoing therapy, mucositis, central line Most chemotherapy: nadir ~ 10 days after rx  Asplenic patients, including sickle cell
  • 7. Definition of fever  38.0  Neonates (< 12 months)  Any immunocompromised patient  Including transplant patients, patients with immunodeficiencies, oncology patients (sustained ≥38 x 1 hour)  38.5  All other patients  These are general guidelines, individual patients/services may have different parameters
  • 8. What etiologies cause fever?  Infectious  Inflammatory  Oncologic  Other: CNS dysfunction, drug fever  Life-threatening conditions
  • 9. Infectious  Systemic  Bacteremia, sepsis, meningitis, endocarditis  Respiratory  URI, sinusitis, otitis media, pharyngitis, pneumonia, bronchiolitis  Abdominal  Urinary tract infection, abscess (liver, kidney, pelvis)  Bone/joint infection  Hardware infection  Central line, VP shunt, G-tube
  • 10. Inflammatory  Kawasaki disease  Juvenile inflammatory arthritis  Lupus  Inflammatory bowel disease  Henoch-Schonlein purpura
  • 12. Life-threatening conditions  Sepsis, febrile neutropenia  Vital sign instability, poor-perfusion, may have altered mental status, disseminated intravascular coagulation  Hemophagocytic lymphohistiocytosis  Splenomegaly, bicytopenia, elevated ferritin, elevated triglycerides, low fibrinogen, hemophagocytosis, low/absent NK cell function, elevated soluble IL2 receptor  Malignant hyperthermia  Following administration of inhaled anesthetics or depolarizing neuromuscular blockers (succinylcholine), at-risk patients include those with myopathy  Muscle rigidity, rhabdomyolysis, acidosis, tachycardia
  • 13. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 14. Assessment  Vital signs  Repeat physical exam  Overall appearance (sick, toxic)  Central/peripheral lines  Incisions/wounds  VP shunt/tracheostomy/gastrostomy tube  Oral mucosa/perineal area for neutropenic patients  Perfusion  Call for help if concerning vital signs/exam  Fellow or attending  Rapid response team (RRT)/PICU
  • 15. Laboratory evaluation  What would you do if the patient has hardware (VP shunt, tracheostomy, gastrostomy tube) or central line? CBC with differential Blood culture CSF (tap VP shunt)
  • 16. Laboratory evaluation  What would you do if the patient has a high risk for sepsis? Immunocompromised Transplant recipient Oncology patient CBC with differential Blood culture Urinalysis and urine culture
  • 17. Laboratory evaluation  What would you do for an infant ≤ 2 months of age? CBC with differential Blood culture Catheterized urinalysis and urine culture Lumbar puncture
  • 18. Laboratory evaluation  Who needs a urinalysis and urine culture? Circumcised males < 6 months Uncircumcised males < 1 year Females < 2 years Immunocompromised patients Patients with history of UTI/pyelonephritis
  • 19. Laboratory evaluation  Who needs a lumbar puncture?  Neonates ≤ 2 months  Ill-appearing  Altered mental status  What tests do you send?  Gram stain and culture  Cell count and differential  Protein and glucose  Extra tube for additional studies  Enteroviral PCR, HSV PCR, CA encephalitis project
  • 20. Laboratory evaluation  Consider CRP, ESR  Consider PT/PTT, fibrinogen  Consider chest x-ray  Consider nasopharyngeal DFA  For immunosuppressed patients consider: Viral PCR studies (ie CMV, EBV, HHV6) Additional imaging (ie ultrasound, CT scan)
  • 21. Objectives  To determine which patients are at high risk of developing sepsis.  To assess patient with fever.  To initiate empiric therapy.
  • 22. Treatment for non-high risk patients  May not need empiric antibiotics  Consider the following issues: Is patient clinically stable? Are the screening laboratory studies suggestive of infection?
  • 23. Treatment for patients with central lines  Ceftriaxone  Vancomycin
  • 24. Treatment for neonates ≤ 2 months  If < 28 days old Ampicillin AND cefotaxime OR Ampicillin AND gentamicin  Consider acyclovir  If 29-60 days old Ceftriaxone ± Ampicillin OR Vancomycin Until CSF results are known (cell count, protein, glucose), initiate therapy with meningitic dosing regimen
  • 25. Treatment for febrile neutropenia  Broad-spectrum antibiotics with Pseudomonas coverage  Ex: use ceftazidime or piperacillin-tazobactam  Consider double coverage for possible resistant Pseudomonas  Ex: add amikacin or tobramycin  Consider gram-positive coverage (central line, skin infections)  Ex: add vancomycin  Consider anaerobic coverage (mucositis, typhlitis)  Ex: use piperacillin-tazobactam or add clindamycin
  • 26. Take home points  Infections are the most common cause of fever in children  During assessment of a child with fever, pay close attention to vital sign changes, overall appearance, and potential sites of infection  Closely monitor for clinical decompensation after antibiotic administration, particularly in patients at high-risk of developing sepsis
  • 27. References  Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000. 36:602-14.  Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin N Am. 2009. 27:525-44.  Palazzi EL. Approach to the child with fever of unknown origin. UpToDate. 2011  Palazzi DL. Etiologies of fever of unknown origin. UpToDate. 2011.  Tolan R. Fever of unknown origin: A diagnostic approach to this vexing problem. Clin Pediatr. 2010;49:207-13.